Comparative chromatography of fresh, freeze-dried and chemically modified human haemoglobin on the cation exchanger Mono S

Přistoupil, T.I.; Kramlová, M.; Fričová, V.; Kraml, J

doi:10.1016/s0021-9673(00)91095-1

“…Pure, well-defined fluorocarbons can indeed be prepared indus trially [9], while the methods to selectively perform the chemical reactions (pyridoxylation, polymerization) re quired to restore the hemoglobin's effectiveness once it has been extracted from its natural environment [1,7,59] still need to be devised. In the present state of the art, these chemical modifications occur more or less at random on the complex polyfunctional hemoglobin molecule, yielding a range of products of diverse molecular weights, and for each molecular weight a number of isomers, including un wanted variations [60,61]. Industrial-scale, pure fluorocar bons can be produced in a reproducible and cost-effective way, while for modified hemoglobins (including those pre pared from genetically engineered material), this still ap pears to be unrealistic.…”

Section: The Fiuosol-da Eramentioning

confidence: 99%

Fluorocarbon-Based in vivo Oxygen Transport and Delivery Systems

Riess¹

1991

View full text Add to dashboard Cite

The approval of Fluosol, a fluorocarbon emulsion for oxygenating the myocardium during the transluminal coronary angioplasty procedure, is a landmark in the field of injectable oxygen carriers, the so-called blood substitutes. This review discusses the advances made since this first emulsion was initially developed about 12 years ago. Attention is focused on the progress achieved in the preparation and selection of new, better-defined and faster-excreted fluorocarbons, and better surfactants, improved emulsions, knowledge of structure/property relationships along with an improved understanding of the physiologic response to their administration. These advances have led to the development of a second generation of highly concentrated, fluid and stable injectable oxygen carriers suitable for a broad range of clinical applications. Prospects for further progress and future generations of emulsions are also outlined.

show abstract

Fluorocarbon‐Based in vivo Oxygen Transport and Delivery Systems

Riess

¹

1991

View full text Add to dashboard Cite

The approval of Fluosol, a fluorocarbon emulsion for oxygenating the myocardium during the transluminal coronary angioplasty procedure, is a landmark in the field of injectable oxygen carriers, the so-called blood substitutes. This review discusses the advances made since this first emulsion was initially developed about 12 years ago. Attention is focused on the progress achieved in the preparation and selection of new, better-defined and faster-excreted fluorocarbons, and better surfactants, improved emulsions, knowledge of structure/property relationships along with an improved understanding of the physiologic response to their administration. These advances have led to the development of a second generation of highly concentrated, fluid and stable injectable oxygen carriers suitable for a broad range of clinical applications. Prospects for further progress and future generations of emulsions are also outlined.

show abstract

Improved Preparation of Soluble Dry Oxyhemoglobin Purified by Carbontetrachloride Treatment of Outdated Packed Erythrocytes

Přistoupil

¹

,

Štěrbíková

²

1992

Int J Artif Organs

0

View full text Add to dashboard Cite

A combination of treating outdated packed red blood cells (PRBCs) with carbontetrachloride, countercurrent dialysis and modified conditions of freeze-drying served to improve and standardize the technology of "stroma-free hemolysate" (SFH) in our laboratory. As a rule, proteins of the final product corresponded to 95% oxyhemoglobin, 3.5% methemoglobin and 1.5% non-hemoglobin ones. In freeze-dried samples stabilized with 0.24 molar saccharides, the weight proportions were 56% hemoglobin, 44% sucrose and/or 62% hemoglobin, and 38% fructose, respectively. If necessary, the saccharides could be rapidly removed from the easily reconstituted SFH by dialysis or chromatography. Analytical parameters were similar to those of chloroform-treated SFH stored dry at -12 degrees C for 4 months. However, the present procedure was easier and SFH samples remained unchanged after dry storage even at +4 degrees C for at least 13 months. This oxyhemoglobin product seems suitable for organ perfusion, further chemical modification and as an analytical standard.

show abstract

Comparative chromatography of fresh, freeze-dried and chemically modified human haemoglobin on the cation exchanger Mono S

Cited by 4 publications

References 3 publications

Fluorocarbon-Based in vivo Oxygen Transport and Delivery Systems

Fluorocarbon-Based in vivo Oxygen Transport and Delivery Systems

Fluorocarbon‐Based in vivo Oxygen Transport and Delivery Systems

Improved Preparation of Soluble Dry Oxyhemoglobin Purified by Carbontetrachloride Treatment of Outdated Packed Erythrocytes

Contact Info

Product

Resources

About